ACAD stock jumps 9% as EU CHMP backs Daybue in 2026

Introduction: what moved ACAD on Friday

Acadia Pharmaceuticals (NASDAQ: ACAD) shares rose sharply on Friday after a positive regulatory development in Europe for its Rett syndrome drug DAYBU (trofinetide). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorisation for DAYBU. If the European Commission approves the recommendation, DAYBU would become the first therapy authorised for neurobehavioral symptoms of Rett syndrome in the European Union. The move mattered for investors because it signals progress after a prior regulatory setback and reopens an EU commercial pathway. The development also arrived alongside a broadly positive session for healthcare equities, even as the broader US market was flat.

CHMP’s positive opinion and what it covers

The CHMP recommendation follows a re-examination procedure and applies to adults and paediatric patients aged five years and older. If the European Commission grants approval, the marketing authorisation would apply across all 27 EU member states, and also extend to Iceland, Liechtenstein, and Norway. The regulatory step is notable because it represents a reversal from the committee’s earlier stance this year. In February, CHMP voted negatively on trofinetide for Rett syndrome after an oral explanation. Friday’s positive opinion is therefore a change in direction rather than a routine procedural update.

The clinical basis: Phase 3 LAVENDER results

The CHMP recommendation was based primarily on positive results from the Phase 3 LAVENDER study. According to the information cited, the trial showed statistically significant improvements in core features of Rett syndrome. The outcomes referenced include the Rett Syndrome Behaviour Questionnaire and the Clinical Global Impression-Improvement scale. The LAVENDER study is central to the case for the medicine because it underpins the benefit-risk assessment regulators must make.

A reversal after February’s negative vote

The timeline is important for understanding why the market responded strongly. CHMP had issued a negative view earlier, and the company moved through a re-examination process. In prior updates referenced in the supplied material, CHMP cited issues including the modest effect observed at 12 weeks and limitations in what the study captured. The negative stance meant the EU expansion catalyst was delayed, keeping attention on the re-examination outcome. Friday’s positive opinion signals that the re-examination process delivered a different conclusion than the February vote.

Stock move and sector context

On the day the news was reported, the healthcare sector was up about 2.76% while the S&P 500 was described as roughly flat. ACAD shares were up 8.60% at $16 at the time of publication, and a subsequent quoted trading level was $16.57. Another data point in the material also described the stock as rising 9% on Friday, consistent with the intraday move. Separately, the stock was described as having surged nearly 10% over the past week to $17.09, trading close to its 52-week high of $18.35.

Technical picture: strong momentum but stretched indicators

The provided technical indicators point to a stock that has moved quickly in a short span. The current price was stated to be 23.1% above the 20-day simple moving average (SMA) of $12.02, indicating strong near-term momentum. At the same time, the RSI was reported at 82.37, which is typically treated as an overbought reading. Longer-term trend signals were also mixed: the 50-day SMA recently crossed below the 200-day SMA, forming a “death cross” in March. This combination of strong short-term price action and weaker longer-term trend signals helps explain why traders may be focused on key price levels.

Key level to watch: $18 resistance area

The stock was described as trading close to a key resistance zone around $18, with $18.35 cited as the 52-week high. With the shares moving toward that area after the CHMP development, the $18 region becomes an important reference point for near-term positioning. The material suggests this level could act as a potential turning point for price action. While regulatory headlines can re-rate expectations, the market often tests prior highs and resistance zones after sharp moves.

What happens next: European Commission decision

The CHMP opinion is not the final step for an EU launch. A final decision from the European Commission is expected in the coming months. If the Commission approves, DAYBU would be authorised for this indication across the EU and certain additional European Economic Area countries cited. For investors, the next milestone is therefore the Commission’s decision and the timing around it, rather than another immediate CHMP vote.

Analyst positioning cited alongside the regulatory update

The supplied material referenced multiple broker reactions around the European development. Baird reiterated an Outperform rating and set a $11.00 price target. Mizuho reiterated an Outperform rating with a $15.00 price target. H.C. Wainwright reiterated a Buy rating and cited a $17.00 price target, and Canaccord Genuity reiterated a Buy rating with a $12.00 price target. It also noted a broader analyst target range cited as $17 to $10 per share. These references reflect how the Street framed the regulatory reversal as a supportive datapoint, while still leaving the final approval step with the European Commission.

Key facts table

Market impact: what the headline changed

The immediate market impact was a sharp, news-driven rise in ACAD shares on a day when the broader market was flat. The move was tied directly to the regulatory signal that the application could advance after a prior negative view in February. The technical backdrop shows the stock already moving with strong momentum, and the CHMP update added a fundamental catalyst to that price action. At the same time, the RSI level cited suggests a stretched short-term setup, even though the price remained below the $18.35 52-week high referenced. The event also reframed the near-term European narrative from setback to potential approval path, with attention shifting to the European Commission timeline.

Why it matters: regulatory risk and milestone clarity

The CHMP reversal matters because it reduces one layer of uncertainty around the EU route, while still leaving the final decision with the European Commission. It also illustrates how re-examination procedures can materially change outcomes. For investors tracking biotech catalysts, the story provides a clear sequence: a negative CHMP vote in February, a re-examination, then a positive opinion, followed by an expected Commission decision in the coming months. The price action and cited technical indicators show how quickly sentiment can shift when a single regulatory milestone turns favourable.

Conclusion

Acadia’s Friday rally was driven by CHMP’s positive recommendation for DAYBU (trofinetide) in Rett syndrome, a reversal from February’s negative vote. The shares moved toward the $18 area that has been flagged as an important resistance zone, with momentum indicators showing strength but also an overbought RSI reading. The next confirmed milestone is the European Commission’s final decision, expected in the coming months, which would determine whether DAYBU becomes the first EU-authorised therapy for these Rett syndrome symptoms.